Last updated on November 2019

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years With OLE


Brief description of study

To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years.

Part 1: Approximately 20 weeks (includes screening and double-blind treatment).

  • Screening will be performed based on the inclusion exclusion criteria specified in the study protocol.
  • Randomize approximately 288 subjects into the double-blind crossover phase.

Part 2: Approximately 100 subjects who complete the double-blind crossover phase will enter part 2, a 6 month open-label safety extension (OLE).

Efficacy will be evaluated in the double-blind part of the trial. Safety will be evaluated in both the double-blind and the OLE.

Clinical Study Identifier: NCT03275922

Find a site near you

Start Over

Blue Sky Neurology (106)

Englewood, CO United States
  Connect »

Precision Clinical Research, LLC. (135)

Lauderdale Lakes, FL United States
  Connect »

Axcess Medical Research (126)

Loxahatchee Groves, FL United States
  Connect »

Laszlo J. Mate, M.D., P.A. (153)

North Palm Beach, FL United States
  Connect »

East Florida Research (143)

Port Saint Lucie, FL United States
  Connect »

Mercy Research (116)

Saint Louis, MO United States
  Connect »

Granger Medical Holladay (111)

Salt Lake City, UT United States
  Connect »

Marshfield Clinic (145)

Marshfield, WI United States
  Connect »

Immunoe Research Centers (131)

Centennial, CO United States
  Connect »